A function of the symptom free survival 5 - fu treated intestine cancer patient from the ratio of the mrna - expression level of thymidine phosphorylase and human dihydropyrimidine dehydrogenase gene

摘要

The present invention is directed to a method for determining whether a patient suffering from cancer is susceptable to a treatment with a 5-Fluoro-Uracil analogon comprising a) determination of Thymidine Phosphorylase mRNA expression in a clinical sample, b) determination of Dihydropyrimindine Dehydrogenase mRNA expression in said clinical sample, and c) determination of the ratio of the value obtained in step a) and the value obtained in step b). If the ratio exceeds a certain cut off, susceptability to 5-FU and/or 5-FU analoga can be expected.